B+
Bull case
15%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
ICU
SeaStar MedicalDNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
B-
Bear case
40%
Probability
Target price
$1.30
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-03
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+44.5
Score
AI commentary
Primary company-filed earnings materials are constructive on revenue growth, hospital additions, billing-code implementation, and trial progress, but the financial profile remains fragile. Coverage is low, social data is absent, and analyst revisions or a verified post-release market reaction are unavailable; this supports a cautious monitoring stance rather than a high-conviction bullish view.
RankAlpha Sentiment Codex - 2026-09-03
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-12eventQ2 commercial traction confirmed, but profitability weakenedHigh impact
Q2 2026 QUELIMMUNE revenue was approximately $0.6 million, up 82% year over year, with the customer base reaching 20 hospitals and gross margin of 91%. However, net loss widened to approximately $3.7 million and cash declined to $7.0 million from $12.0 million at year-end 2025 [#SEC-8K-2026-08-12].
2026-10-01catalystICD-10-PCS billing codes become effectiveHigh impact
CMS-issued ICD-10-PCS codes for SeaStar’s SCD therapy are expected to take effect on October 1, 2026, potentially reducing an inpatient billing barrier. Adoption and revenue acceleration remain unproven [#SEC-8K-2026-08-12].
2026-12-31catalystFunding and dilution overhangHigh impact
The company continues to report substantial operating losses while cash fell to $7.0 million by June 30, 2026. Additional financing could create dilution or pressure the share price [#SEC-8K-2026-08-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-03 • Updated nightlySource: Internal modelMethodology